id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1978-N-2157-0003,FDA,FDA-1978-N-2157,Internal Memorandum from Director Division of OTC Drug Evaluation (HFN-810) to Dockets Management Branch (HFA-305),Other,Memorandum,2004-02-02T05:00:00Z,2004,2,,,2019-06-05T13:39:26Z,,0,0,09000064805a6712